Ask AI

Maximizing Efficacy and Minimizing Toxicities With Antibody–Drug Conjugates in Breast Cancer

Share

Program Content

Events

  • Live Event APPlexus Fall 2025: Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer
    APPlexus Fall 2025: Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

  • ADCs in Breast Cancer
    Maximizing Efficacy and Minimizing Toxicities With Antibody–Drug Conjugates in Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 16, 2025

Provided by

ProCE Banner

Supporters

The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Supported by an educational grant from Lilly.

Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Supported by an educational grant from Lilly.

Maximizing Efficacy and Minimizing Toxicities With Antibody–Drug Conjugates in Breast Cancer

Supported by an educational grant from Gilead Sciences, Inc.

The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Supported by an educational grant from BeOne Medicines.

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Supported by an educational grant from Genmab US, Inc.

BeOne Medicines

Genmab US, Inc.

Gilead Sciences, Inc.

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner